# US 2008/0306085 A1 · Non-imidazole aryloxyalkylamines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306085 A1
- Document ID: US20080306085A1
- Status: Published application
- Kind: A1
- Application number: 12/194,653
- Filed: 2008-08-20
- Published: 2008-12-11
- Earliest claimed: 2000-08-08
- Inventors: Richard Apodaca; Nicholas I. Carruthers; Curt A. Dvorak; Dale A. Rudolph; Chandravadan R. Shah; Wei Xiao
- Web page: https://patentgrep.com/patent/US20080306085A1

## CPC

- C07D 207/325: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4465: only substituted in position 4
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/16: Otologicals
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 217/22: by carbon atoms having at least two bonds to oxygen atoms
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07C 335/32: having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
- C07D 207/335: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 211/22: by oxygen atoms
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/58: attached in position 4
- C07D 213/36: Radicals substituted by singly-bound nitrogen atoms (nitro radicals C07D213/26)
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/42: Sulfur atoms
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 233/84: Sulfur atoms
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 235/26: Oxygen atoms
- C07D 239/34: One oxygen atom
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 257/04: Five-membered rings
- C07D 277/36: Sulfur atoms
- C07D 295/088: to an acyclic saturated chain
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/112: with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/205: Radicals derived from carbonic acid
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 317/28: Radicals substituted by nitrogen atoms (nitro radicals C07D317/16)
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

## Claims

### Claim at position 1

-53. (canceled)

### Claim 54

A method of inhibiting histamine H3 receptor activity in a subject, comprising administering an effective amount of a compound of formula (I) to a subject in need of such inhibition of histamine H3 receptor activity, wherein the compound of formula (I) is:
wherein Ra, and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl, (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1 Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, phenyl, naphthyl, (naphthyl)C1-6 alkylene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene,
L5 is C1-5 alkylene,
L6 is C1-5 alkylene,
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocycyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl)C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 55

A method of treating a subject having a disease or condition modulated by histamine H3 receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 56 (depends on 55)

A method of claim 55, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

### Claim 57

A method for treating a disease or condition modulated by at least one receptor selected from the histamine H1 receptor and the histamine H3 receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of formula (I), said method providing a jointly therapeutically effective amount of said compounds, wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 58 (depends on 57)

The method of claim 57 wherein the histamine H1 receptor antagonist and the compound of formula (I) are present in the same dosage form.

### Claim 59

A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H2 receptor and the histamine H3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of formula (I) said method providing a jointly therapeutically effective amount of said compounds, wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 60 (depends on 59)

The method of claim 59 wherein the histamine H2 receptor antagonist and the compound of formula (I) are present in the same dosage form.

### Claim 61

A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-3 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8alkyl, C3-8alkenyl, C3-7cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 62

A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent,
Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 63

A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C9-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent;
Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl, ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 64

A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1 Q)R6R7, —C(L1 Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent,
Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.

### Claim 65

A method for studying disorders mediated by the histamine H3 receptor, comprising using an 18F-labeled compound of formula (I) as a positron emission tomography (PET) molecular probe, wherein the compound of formula (I) is:
wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
(C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
n is 0-4;
one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
G is a nitrogen-containing group selected from one of the following:
—OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
wherein:
L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
L4 is C1-5 alkylene;
L5 is C1-5 alkylene;
L6 is C1-5 alkylene;
L7 is C1-5 alkylene or absent,
Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
L3 is not phenyl or naphthyl.
